Wedbush downgraded iTeos Therapeutics (ITOS) to Neutral from Outperform.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- iTeos Therapeutics Announces Strategic Wind Down Plan
- iTeos Therapeutics announces intention to wind down operations
- iTeos Therapeutics price target lowered to $13 from $16 at Wells Fargo
- iTeos Therapeutics price target lowered to $12 from $16 at Piper Sandler
- Leerink downgrades iTeos Therapeutics after termination of TIGIT program